NIMG-72. CEREBRAL BLOW FLOW AND SUV TRENDS IN PET/MRI FOLLOWING BEVACIZUMAB ADMINISTRATION IN GLIOBLASTOMA

摘要

BACKGROUNDBevacizumab (BEV) is an antibody directed at vascular endothelial growth factor (VEGF) and holds FDA approval in recurrent glioblastoma (GBM). Pseudoprogression with necrosis is a common clinical concern in GBM, and BEV is useful in treating both tumor and necrosis. Though conventionally viewed as anti-angiogenic therapy, we propose that metabolic effects occur following BEV infusion, and these changes may be informative regarding lesion etiology. Preliminary SUV results from our pilot FDG-PET/MRI study were presented previously. We are providing an updated analysis here, incorporating cerebral blood flow (CBF) measurements.